Boston An independent LDT provider

Press releases

July 5, 2022

CPT PLA Code for the IMMray™ PanCan-d test approved

Read press release
June 30, 2022

The PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phase

Read press release
June 27, 2022

Invitation to Immunovia’s Presentation of PanFAM-1 Results

Read press release
June 27, 2022 | REGULATORY

PanFAM-1 Results Partly Inconclusive

Read press release
June 2, 2022 | REGULATORY

Philipp Mathieu appointed CEO of Immunovia AB

Read press release
May 23, 2022

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states

Read press release
May 17, 2022

Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states

Read press release
May 16, 2022

Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US

Read press release
April 28, 2022 | REGULATORY

Immunovia Publishes Interim Report January-March 2022

Read press release
April 21, 2022

Invitation to Immunovia’s Q1 presentation

Read press release
April 14, 2022 | REGULATORY

Immunovia CPT PLA Code submission for the IMMray™ PanCan-d test is on the agenda of American Medical Association

Read press release
April 7, 2022 | REGULATORY

Communiqué from the Annual General Meeting in Immunovia AB

Read press release
1 2 3 23